Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

IMS 2026 | Patient satisfaction with subcutaneous isatuximab in myeloma: IRAKLIA and IZALCO

Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, discusses patient experience with subcutaneous isatuximab administered via an on-body injector (OBI) in multiple myeloma. Dr Cerchione highlights findings from the Phase III IRAKLIA (NCT05405166) and Phase II IZALCO (NCT05704049) trials, emphasizing patient satisfaction, convenience, and treatment preference. He also discusses the potential of OBI administration to reduce hospital visits and facilitate home-based treatment. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

It’s really important to consider the data coming from IZALCO and IRAKLIA that are respectively the trials that have shown the non-inferiority of Isa-Pom-Dex and Isa-Kd in subcutaneous versus intravenous. Subcutaneous administration was performed through OBI, that is a dome body injection, a small button, a small tool that we place on the patient’s abdomen and is safe, really fast, and really comfortable...

It’s really important to consider the data coming from IZALCO and IRAKLIA that are respectively the trials that have shown the non-inferiority of Isa-Pom-Dex and Isa-Kd in subcutaneous versus intravenous. Subcutaneous administration was performed through OBI, that is a dome body injection, a small button, a small tool that we place on the patient’s abdomen and is safe, really fast, and really comfortable. So this impacted positively with the adherence and compliance of our patients. The last data showed the patient’s reported outcomes that are absolutely outstanding. And this is in some way in line also with the healthcare professional outcomes that are particularly brilliant in the idea that through OBI we can optimize not only the space in the hospital but also the timing for patients, for healthcare professionals and in some way also for caregivers and for all the team, the entourage that guides the patients in this journey. I think that these data are particularly impactful on our daily practice because we can optimize our outpatient setting and if we consider that inside IRAKLIA there are some patients treated in a domestic setting, I think that we can imagine in a future that I hope that is not so far that we can drive at least the chronic patients after some cycles, hopefully the six cycles of the trial at home. So in the idea that we can in some way fight against a chronic disease, putting the patients in the more comfortable possibilities. So the idea of continuing the treatment at home, that is the best because he can enjoy the loved ones and can enjoy their daily life.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.